News + Filings Transactions
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
|
|
Kulkarni Samarth
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 06/12/2023 |
4
| Kulkarni Samarth (Director) has filed a Form 4 on Repare Therapeutics Inc.|
Txns:
| Granted 27,200 options to buy
@ $11.66, valued at
$317.2k
|
|
| 06/01/2023 |
4
| Kulkarni Samarth (CEO) has filed a Form 4 on CRISPR Therapeutics AG|
Txns:
| Sold 7,301 shares
@ $63.6149, valued at
$464.5k
Sold 5,999 shares
@ $64.4577, valued at
$386.7k
Sold 9,300 shares
@ $65.63, valued at
$610.4k
Sold 2,400 shares
@ $66.8338, valued at
$160.4k
Exercised 25,000 options to buy
@ $19.12, valued at
$478k
|
|
| 05/30/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/17/2023 |
4
| Kulkarni Samarth (Director) has filed a Form 4 on Black Diamond Therapeutics, Inc.|
Txns:
| Granted 16,500 options to buy
@ $1.82, valued at
$30k
|
|
| 04/27/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/25/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 03/31/2023 |
4
| Kulkarni Samarth (CEO) has filed a Form 4 on CRISPR Therapeutics AG|
Txns:
| Sold 19,719 shares
@ $44.3733, valued at
$875k
Sold 5,281 shares
@ $44.7844, valued at
$236.5k
Exercised 25,000 options to buy
@ $19.12, valued at
$478k
|
|
| 03/14/2023 |
4
| Kulkarni Samarth (CEO) has filed a Form 4 on CRISPR Therapeutics AG|
Txns:
| Paid exercise price by delivering 5,358 shares
@ $43.22, valued at
$231.6k
Paid exercise price by delivering 4,086 shares
@ $43.22, valued at
$176.6k
Exercised 11,833 restricted stock units
@ $0
Granted 188,000 options to buy
@ $43.22, valued at
$8.1M
Granted 77,000 restricted stock units
@ $0
Exercised 9,000 restricted stock units
@ $0 |
|
| 03/01/2023 |
4
| Kulkarni Samarth (CEO) has filed a Form 4 on CRISPR Therapeutics AG|
Txns:
| Sold 10,180 shares
@ $47.7122, valued at
$485.7k
Sold 13,720 shares
@ $48.5725, valued at
$666.4k
Sold 1,100 shares
@ $49.1986, valued at
$54.1k
Exercised 25,000 options to buy
@ $19.12, valued at
$478k
|
|
| 02/22/2023 |
4
| Kulkarni Samarth (CEO) has filed a Form 4 on CRISPR Therapeutics AG|
Txns:
| Paid exercise price by delivering 6,373 shares
@ $48.26, valued at
$307.6k
Exercised 13,250 restricted stock units
@ $0 |
|
| 01/31/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/30/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/08/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/06/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/30/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/28/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 09/30/2022 |
4
| Kulkarni Samarth (CEO) has filed a Form 4 on CRISPR Therapeutics AG|
Txns:
| Sold 23,200 shares
@ $64.5782, valued at
$1.5M
Sold 1,800 shares
@ $64.97, valued at
$116.9k
Exercised 25,000 options to buy
@ $16.21, valued at
$405.3k
|
|
| 08/31/2022 |
4
| Kulkarni Samarth (CEO) has filed a Form 4 on CRISPR Therapeutics AG|
Txns:
| Sold 4,073 shares
@ $66.1405, valued at
$269.4k
Sold 20,764 shares
@ $66.975, valued at
$1.4M
Sold 163 shares
@ $67.64, valued at
$11k
Exercised 25,000 options to buy
@ $16.21, valued at
$405.3k
|
|
| 08/18/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/29/2022 |
4
| Kulkarni Samarth (CEO) has filed a Form 4 on CRISPR Therapeutics AG|
Txns:
| Sold 6,933 shares
@ $75.6385, valued at
$524.4k
Sold 700 shares
@ $76.373, valued at
$53.5k
Sold 700 shares
@ $77.7929, valued at
$54.5k
Sold 12,759 shares
@ $75.732, valued at
$966.3k
Sold 3,308 shares
@ $76.2944, valued at
$252.4k
Sold 600 shares
@ $77.9717, valued at
$46.8k
Exercised 8,333 options to buy
@ $12.57, valued at
$104.7k
Exercised 16,667 options to buy
@ $16.21, valued at
$270.2k
|
|
| 07/05/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/01/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/13/2022 |
4
| Kulkarni Samarth (Director) has filed a Form 4 on Black Diamond Therapeutics, Inc.|
Txns:
| Granted 15,000 options to buy
@ $2.14, valued at
$32.1k
|
|
| 05/16/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/14/2022 |
4
| Kulkarni Samarth (CEO) has filed a Form 4 on CRISPR Therapeutics AG|
Txns:
| Paid exercise price by delivering 5,487 shares
@ $62.56, valued at
$343.3k
Paid exercise price by delivering 4,153 shares
@ $61.08, valued at
$253.7k
Exercised 11,834 restricted stock units
@ $0
Exercised 9,000 restricted stock units
@ $0 |
|
| 02/22/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/22/2021 |
4
| Kulkarni Samarth (CEO) has filed a Form 4 on CRISPR Therapeutics AG|
Txns:
| Exercised 17,750 options to buy
@ $1.81, valued at
$32.1k
|
|
| 12/07/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/03/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/18/2021 |
4
| Kulkarni Samarth (CEO) has filed a Form 4 on CRISPR Therapeutics AG|
Txns:
| Granted 43,000 options to buy
@ $97, valued at
$4.2M
Exercised 33,000 options to buy
@ $1.81, valued at
$59.7k
|
|
| 09/03/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 08/06/2021 |
4
| Kulkarni Samarth (CEO) has filed a Form 4 on CRISPR Therapeutics AG|
Txns:
| Sold 1,500 shares
@ $125.02, valued at
$187.5k
Sold 1,000 shares
@ $126.67, valued at
$126.7k
Sold 4,700 shares
@ $127.82, valued at
$600.8k
Sold 13,499 shares
@ $128.85, valued at
$1.7M
Sold 6,819 shares
@ $129.82, valued at
$885.2k
Sold 2,482 shares
@ $130.51, valued at
$323.9k
Exercised 1,500 options to buy
@ $12.57, valued at
$18.9k
Exercised 28,500 options to buy
@ $12.57, valued at
$358.2k
|
|
| 06/22/2021 |
4
| Kulkarni Samarth (Director) has filed a Form 4 on Black Diamond Therapeutics, Inc.|
Txns:
| Granted 15,000 options to buy
@ $12.55, valued at
$188.3k
|
|
| 06/17/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
|
|
|